Literature DB >> 21508832

Major risk of blood transfusion in hemolytic anemia patients.

Nagla Omar1, Khaled Salama, Sonya Adolf, Gamila S M El-Saeed, Nagwa Abdel Ghaffar, Nivin Ezzat.   

Abstract

Thalassemia is a congenital hemolytic disease caused by defective globin synthesis treated by blood transfusion. Transfusion-transmitted infections still make a great challenge in the management of patients with thalassemia major. The most important worldwide transfusion-transmitted infections are hepatitis B virus (HBV), hepatitis C virus (HCV) and HIV. The objective of this study is to update the prevalence of the three major transfusion-transmitted infections HCV, HBV and HIV among thalassemic patients followed up in the Hematology Department, Children Hospital, Cairo University. The study included 174 multitransfused thalassemic patients (162 major and 12 intermedia), registered at the Pediatric Hematology Clinic, Cairo University. Their age ranged from 2 to 27 years with a mean of 11.26 ± 5.4 years. Patients were subjected to full history taking, stressing on history of blood transfusions (onset, frequency and duration) at a single or multiple centers and abdominal examination. Laboratory investigations including complete blood count, aminotransferases (aspartate aminotransferase and alanine aminotransferase), ferritin and viral markers of HBV surface antigen (HBsAg), HCV antibodies (anti-HCV) and anti-HIV were assayed for all cases by a third-generation ELISA method. HCV PCR was performed for 75 cases. Of the 174 patients, none of them were HBsAg and anti-HIV positive. However, 90 patients were anti-HCV positive (51.7%). HCV PCR was positive in 56 patients (74.3%) of the 75 with positive antibody tested. HCV antibody positivity is statistically significant with age of the patient, serum ferritin and liver transaminases (P < 0.01). HCV-RNA by PCR positivity was significantly related to patients' age and serum ferritin (P < 0.05). Serum ferritin showed statistically significant positive correlation with liver transaminases. Despite the decrease in prevalence of HCV antibody in our patients from 71% in 1995 to 51.7% in our study, yet HCV infection still represents a major health problem for our thalassemic patients, which requires more attention and efforts to challenge. There is a dramatic decrease in the prevalence of HBV infection over the last decade, thanks to mass compulsory vaccination and blood screening. HIV infection does not represent a problem owing to very low population prevalence.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21508832     DOI: 10.1097/MBC.0b013e3283451255

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  10 in total

1.  Transfusion complications in thalassemia patients: a report from the Centers for Disease Control and Prevention (CME).

Authors:  Elliott Vichinsky; Lynne Neumayr; Sean Trimble; Patricia J Giardina; Alan R Cohen; Thomas Coates; Jeanne Boudreaux; Ellis J Neufeld; Kristy Kenney; Althea Grant; Alexis A Thompson
Journal:  Transfusion       Date:  2013-07-25       Impact factor: 3.157

Review 2.  Potential for human immunodeficiency virus parenteral transmission in the Middle East and North Africa: an analysis using hepatitis C virus as a proxy biomarker.

Authors:  Yousra A Mohamoud; F DeWolfe Miller; Laith J Abu-Raddad
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

3.  CMV, B and C hepatitis among multi-transfused hereditary hemolytic Anemia children: an updated Egyptian experience.

Authors:  Laila M Sherief; Seham M Ragab; Mohamed A Helwa; Naglaa M Kamal; Mona R Afify; Rasha T S Mohammed; Ghada Abd Elmoniem Mokhtar; Hanan S Sherbiny
Journal:  Ital J Pediatr       Date:  2021-05-26       Impact factor: 2.638

Review 4.  The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis.

Authors:  Yousra A Mohamoud; Ghina R Mumtaz; Suzanne Riome; Dewolfe Miller; Laith J Abu-Raddad
Journal:  BMC Infect Dis       Date:  2013-06-24       Impact factor: 3.090

5.  Transfusion transmitted hepatitis: where do we stand now? A one center study in upper egypt.

Authors:  Amel Abdel Magied El-Faramawy; Omnia Fathy El-Rashidy; Perihan Hamdy Tawfik; Galal Helmy Hussein
Journal:  Hepat Mon       Date:  2012-04-30       Impact factor: 0.660

Review 6.  Al-hijamah and oral honey for treating thalassemia, conditions of iron overload, and hyperferremia: toward improving the therapeutic outcomes.

Authors:  Salah Mohamed El Sayed; Hussam Baghdadi; Ashraf Abou-Taleb; Hany Salah Mahmoud; Reham A Maria; Nagwa S Ahmed; Manal Mohamed Helmy Nabo
Journal:  J Blood Med       Date:  2014-10-30

7.  Liver Enzymes in Children with beta-Thalassemia Major: Correlation with Iron Overload and Viral Hepatitis.

Authors:  Khaled M Salama; Ola M Ibrahim; Ahmed M Kaddah; Samia Boseila; Leila Abu Ismail; May M Abdel Hamid
Journal:  Open Access Maced J Med Sci       Date:  2015-05-28

Review 8.  Hepatitis C virus viremic rate in the Middle East and North Africa: Systematic synthesis, meta-analyses, and meta-regressions.

Authors:  Manale Harfouche; Hiam Chemaitelly; Silva P Kouyoumjian; Sarwat Mahmud; Karima Chaabna; Zaina Al-Kanaani; Laith J Abu-Raddad
Journal:  PLoS One       Date:  2017-10-31       Impact factor: 3.240

9.  Reply: To PMID 22366833.

Authors:  Magy S Abdelwahab
Journal:  Ann Saudi Med       Date:  2013 Jan-Feb       Impact factor: 1.526

10.  Prevalence of Sero-Molecular Markers of Hepatitis C and B Viruses among Patients with β-Thalassemia Major in Northern West Bank, Palestine.

Authors:  Kamal Dumaidi; Amer Al-Jawabreh; Fekri Samarah; Maha Rabayaa
Journal:  Can J Infect Dis Med Microbiol       Date:  2018-09-05       Impact factor: 2.471

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.